NASDAQ:OBLN - Obalon Therapeutics Stock Price, Forecast & News

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

Obalon Therapeutics shares reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

Obalon Therapeutics Inc (NASDAQ:OBLN) released its quarterly earnings data on Thursday, February, 27th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.06. The business earned $0.79 million during the quarter. Obalon Therapeutics had a negative return on equity of 228.96% and a negative net margin of 607.48%. View Obalon Therapeutics' Earnings History.

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, May 8th 2020. View Earnings Estimates for Obalon Therapeutics.

2 brokerages have issued 12-month price objectives for Obalon Therapeutics' stock. Their forecasts range from $10.00 to $15.00. On average, they expect Obalon Therapeutics' stock price to reach $12.50 in the next year. This suggests a possible upside of 839.8% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.

News coverage about OBLN stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obalon Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Obalon Therapeutics.

Some companies that are related to Obalon Therapeutics include Neuronetics (STIM), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Delcath Systems (DCTH), T2 Biosystems (TTOO), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Interpace Diagnostics Group (IDXG), Biostage (BSTG), Neovasc (NVCN), Endologix (ELGX), RA Medical Systems (RMED), DarioHealth (DRIO), Titan Medical (TMDI) and Hancock Jaffe Laboratories (HJLI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), Opko Health (OPK), Titan Pharmaceuticals (TTNP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Zynerba Pharmaceuticals (ZYNE).

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

Obalon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Oxford Asset Management LLP (0.55%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

OBLN stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP. Company insiders that have bought Obalon Therapeutics stock in the last two years include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Insider Buying and Selling for Obalon Therapeutics.

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OBLN stock can currently be purchased for approximately $1.33.

Obalon Therapeutics has a market capitalization of $10.28 million and generates $9.10 million in revenue each year. Obalon Therapeutics employs 100 workers across the globe.View Additional Information About Obalon Therapeutics.

The official website for Obalon Therapeutics is http://www.obalon.com/.

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]